The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

Stopped early · Not applicable

Conditions studied: COPD

In brief

This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with HFA-134a and 10 receiving a placebo.

Key facts

Study ID

NCT00238082

Run by

National Jewish Health

People needed

20

Starts

1999-11-01

Expected to finish

2005-02-01

Last updated by the study team

2017-03-29

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• COPD diagnosis
• FEV1/FVC<70%
• FEV1 50-80% predicted
• Albuterol response of <12% and <200mL or methacholine PC20 > 8mg/mL
• RV > 120% predicted
• DLCO < 80%
• smokers and nonsmokers
• Lower age limit 45 years

You may not qualify if…

• Asthma
• Other chronic airway or parenchymal lung disease
• Other comorbid illness (including but not limited to DM, MI or CAD-related intervention in 6 months, neurologic disease, syncope)
• Use of any steroid (oral, IV, nasal, pulmonary) within 12 weeks
• Use of theophylline, leukotriene modifiers within 12 weeks
• Use of long-acting beta-agonists (formoterol, salmeterol) or anticholinergic (tiotropium)

Where it is running

• National Jewish Medical and Research Center — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.